Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

Current trends in drug development point toward a growing number of therapies that are targeting smaller patient populations. As the batch sizes required to manufacture clinical and commercial supply ...

The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech ...

Over the years, I’ve had the privilege of working alongside some extraordinary leaders. When I reflect on those who have left the most lasting impact on me, I often describe them as having what I call ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and ...

Delivering reliable, high-quality software at speed requires more than fast coding—it demands a smarter approach to testing. That’s where the Shift-Left methodology comes in. By moving testing ...

France's Early Access Program (EAP) is a critical pathway for patients with severe or rare conditions to swiftly access innovative therapies, having granted over 120,000 patients early access since ...